Capacity building for assessing new technologies: approaches to examining personalized medicine in practice
- 1 July 2010
- journal article
- Published by Future Medicine Ltd in Personalized Medicine
- Vol. 7 (4), 427-439
- https://doi.org/10.2217/pme.10.36
Abstract
This article focuses on the overarching question: how can we use existing data to develop the capacity to improve the evidence base on personalized medicine technologies and particularly regarding their utilization and clinical utility? We focus on data from health payers who are key stakeholders in capacity building, as they need data to guide decisions and they develop data as part of operations. Broadly defined, health payers include insurance carriers, third party payers, health-plan sponsors and organized delivery systems. Data from health payers have not yet been widely used to assess personalized medicine. Now, with an increasing number of personalized technologies covered and reimbursed by health payers, and an increasing number of emerging technologies that will require policy decisions, there is a great opportunity to develop the evidence base using payer data and by engaging with these stakeholders. Here, we describe data that are available from, and are being developed by, health payers and assess how these data can be further developed to increase the capacity for future research, using three examples. The examples suggest that payer data can be used to examine clinical utility and approaches can be developed that simultaneously address the characteristics of personalized medicine, real world data and organizations. These examples can now help us to elucidate how to best examine clinical utility in actual practice and build evaluation approaches that can be applied to future technologies.Keywords
This publication has 17 references indexed in Scilit:
- Women's experiences with genomic testing for breast cancer recurrence riskCancer, 2010
- Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patientsCancer, 2009
- Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analysesPersonalized Medicine, 2009
- Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?Genetics in Medicine, 2009
- Challenges and opportunities for evidence-based genetics practiceGenetics in Medicine, 2009
- Closing the Evidence Gap in the Use of Emerging Testing Technologies in Clinical PracticeJAMA, 2008
- The Evidence Dilemma In Genomic MedicineHealth Affairs, 2008
- Making performance indicators work: experiences of US Veterans Health AdministrationBMJ, 2007
- Insurers And ‘Targeted Biologics' For Cancer: A Conversation With Lee N. NewcomerHealth Affairs, 2007
- Initial development of an evidence base for personalized medicine’s translation to clinical practice and health policyPersonalized Medicine, 2006